17 / 28
Scher, JAMA Oncol, 2016
PSA decline ≥50: 0% AR-V7+
PSA decline <50%: 20%AR-V7+
No association between AR-V7 and response to taxanes
•
AR-V7 associated to poor OS
•
More favorable survival with taxanes vs ART-therapies (HR,0.24)